Plenary Session: Artificial Intelligence in Cancer Care: Opportunities, Challenges, and Governance

Education in this topic is important as AI is increasingly incorporated into care settings. Practitioners may not be aware of the way AI is currently being used or of its potential future application. Additionally, healthcare professionals need to be informed of the policy environment for the safe and effective use of AI in healthcare settings.

Target Audience

This program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Identify current and potential uses, risks, and ethical implications of artificial intelligence in cancer care.
  • Describe safeguards that can be put into place to protect patients.
Additional information
Supporters: 

Supported by educational grants from AstraZeneca; BeiGene; Coherus BioSciences; Eisai, Inc.; Exact Sciences; Ferring Pharmaceuticals; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lantheus; Lilly; Menarini-Stemline; Novartis; Novocure; Pharmacosmos Therapeutics Inc.; Puma Biotechnology; and Taiho Oncology, Inc. Supported by independent medical education grants from AbbVie; ADC Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; Jazz Pharmaceuticals; and Rigel Pharmaceuticals, Inc. Supported by independent educational grants from Daiichi Sankyo; Incyte Corporation; and Merck & Co., Inc., Rahway, NJ, USA. This activity is supported by funding from Blue Earth Diagnostics, A Bracco Company. This educational activity is supported by a medical education grant from Exelixis, Inc. This project has been made possible in part by a grant from Varian Medical Systems, a Siemens Healthineers company/Global Medical Education Grant Program.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
06/15/2025
Course expires: 
03/01/2026
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2025 Annual Conference

Moderator

Clifford S. Goodman, PhD
Consultant, Health Care Technology & Policy

Panelists

Dennis Chornenky, MBA, MPH, MS
CEO, Domelabs AI

Peter D. Stetson, MD, MA
Memorial Sloan Kettering Cancer Center

Tufia C. Haddad, MD
Mayo Clinic Comprehensive Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Dennis Chornenky, MBA, MPH, MS
Tufia C. Haddad, MD
Peter D. Stetson, MD, MA

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Clifford S. Goodman, PhD
Bayer HealthCare: Consulting Fee
Genentech, Inc.: Honoraria
Janssen Pharmaceutica Products, LP: Consulting Fee
Medtronic, Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

NCCN Staff Disclosures

The planner listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal Denlinger, MD, FACP 
2seventy bio: Grant/Research Support
AbbVie, Inc.: Grant/Research Support
Bluebird bio: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc: Grant/Research Support
GSK: Grant/Research Support
Pfizer Inc: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-25-068-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until March 1, 2026. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing